Prognostic value of tripartite motif containing 29 expression in patients with gastric cancer following surgical resection

Wang,Chenghu; Zhou,Yi; Chen,Beibei; Yuan,Weiwei; Huang,Jinxi

doi:10.3892/ol.2018.8059

Prognostic value of tripartite motif containing 29 expression in patients with gastric cancer following surgical resection

Authors:
- Chenghu Wang
- Yi Zhou
- Beibei Chen
- Weiwei Yuan
- Jinxi Huang
View Affiliations

Affiliations: Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Anesthesiology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China, Department of Internal Medicine of Digestive Tract Tumor, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China
Published online on: February 15, 2018 https://doi.org/10.3892/ol.2018.8059
Pages: 5792-5798

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tripartite motif containing 29 (TRIM29) dysregulation serves an important function in the progression of numerous types of cancer, but its function in the prognosis of patients with gastric cancer remains unknown. The present study assessed the prognostic value of TRIM29 in patients with gastric cancer following surgical resection. A total of 243 fresh gastric adenocarcinoma and adjacent normal tissues were continuously retrieved from patients who underwent curative surgery for gastric cancer at the Cancer Hospital of Henan Province (Zhengzhou, China) between January 2005 and December 2011. The reverse transcription‑quantitative polymerase chain reaction was performed to assess TRIM29 expression. The association between TRIM29 expression and clinicopathological features and prognosis was subsequently evaluated. The results of the present study revealed that the expression of TRIM29 was increased in the gastric cancer tissues compared with the normal adjacent tissues, and that upregulated expression of TRIM29 was associated with tumor cell differentiation, tumor stage, lymph node metastasis, and tumor‑node‑metastasis (TNM) stage. In the training and validation data, high TRIM29 expression was associated with poor overall survival in patients with gastric cancer. Furthermore, multivariate analysis identified that TRIM29 expression was an independent prognostic factor for overall survival, in addition to TNM stage and Lauren classification. Combining TRIM29 expression with the TNM staging system generated a novel predictive model that exhibited improved prognostic accuracy for overall survival in patients with gastric cancer. The present study revealed that TRIM29 was an independent adverse prognostic factor in patients with gastric cancer. Incorporating TRIM29 expression level into the TNM staging system may improve risk stratification and render prognosis more accurate in patients with gastric cancer.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 12:17–20. 2006. View Article : Google Scholar : PubMed/NCBI
3	Chen WQ, Zheng RS, Zhang SW, Zeng HM and Zou XN: The incidences and mortalities of major cancers in China, 2010. Chin J Cancer. 33:402–405. 2014.PubMed/NCBI
4	Washington K: 7th edition of the AJCC cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010. View Article : Google Scholar : PubMed/NCBI
5	Thrumurthy SG, Chaudry MA, Hochhauser D and Mughal M: The diagnosis and management of gastric cancer. BMJ. 347:f63672013. View Article : Google Scholar : PubMed/NCBI
6	Stadtländer CT and Waterbor JW: Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis. 20:2195–2208. 1999. View Article : Google Scholar : PubMed/NCBI
7	Figueiredo C, Garcia-Gonzalez MA and Machado JC: Molecular pathogenesis of gastric cancer. Helicobacter. 18 Suppl 1:S28–S33. 2013. View Article : Google Scholar
8	Kapp LN, Painter RB, Yu LC, van Loon N, Richard CW III, James MR, Cox DR and Murnane JP: Cloning of a candidate gene for ataxia-telangiectasia group D. Am J Hum Genet. 51:45–54. 1992.PubMed/NCBI
9	Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et al: The tripartite motif family identifies cell compartments. EMBO J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
10	Hatakeyama S: Early evidence for the role of TRIM29 in multiple cancer models. Expert Opin Ther Targets. 20:767–770. 2016. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–428. 2001. View Article : Google Scholar : PubMed/NCBI
12	Kanno Y, Watanabe M, Kimura T, Nonomura K, Tanaka S and Hatakeyama S: TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta Histochem. 116:708–712. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sun H, Dai X and Han B: TRIM29 as a novel biomarker in pancreatic adenocarcinoma. Dis Markers. 2014:3178172014. View Article : Google Scholar : PubMed/NCBI
14	Zhou ZY, Yang GY, Zhou J and Yu MH: Significance of TRIM29 and β-catenin expression in non-small-cell lung cancer. J Chin Med Assoc. 75:269–274. 2012. View Article : Google Scholar : PubMed/NCBI
15	Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Ulhøi BP, et al: Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol. 182:339–349. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lai W, Zheng X, Huang Q, Wu X and Yang M: Down-regulating ATDC inhibits the proliferation of esophageal carcinoma cells. Eur Rev Med Pharmacol Sci. 18:3511–3516. 2014.PubMed/NCBI
17	Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M and Simeone DM: Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell. 15:207–219. 2009. View Article : Google Scholar : PubMed/NCBI
19	Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klären R, Gröne EF, Wiesel M, Güdemann C, et al: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: A gene expression analysis on total and microdissected prostate tissue. Am J Pathol. 160:2169–2180. 2002. View Article : Google Scholar : PubMed/NCBI
20	Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, et al: Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 59:5464–5470. 1999.PubMed/NCBI
21	Hosoi Y, Kapp LN, Murnane JP, Matsumoto Y, Enomoto A, Ono T and Miyagawa K: Suppression of anchorage-independent growth by expression of the ataxia-telangiectasia group D complementing gene, ATDC. Biochem Biophys Res Commun. 348:728–734. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zhou XM, Sun R, Luo DH, Sun J, Zhang MY, Wang MH, Yang Y, Wang HY and Mai SJ: Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget. 7:13634–13650. 2016.PubMed/NCBI
23	Qiu F, Xiong JP, Deng J and Xiang XJ: TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.PubMed/NCBI